Posted on April 13 2026 | By Dr. Maya Patel, Head of Translational Oncology, NovaCure Therapeutics
| Cohort | Dose (mg) | Patients (n) | Safety | Pharmacodynamics (PD) | |--------|-----------|--------------|--------|----------------------| | Single‑Ascending Dose (SAD) | 10 → 200 | 30 | Mostly Grade 1–2 AEs (nausea, mild headache). No DLTs up to 200 mg. | Dose‑dependent reduction of peripheral IL‑6 (≈ 60 % at 150 mg). | | Multiple‑Ascending Dose (MAD) | 50 → 150 mg BID | 24 | One Grade 3 transient ALT elevation (resolved on hold). | Sustained NF‑κB inhibition (> 70 % baseline) in peripheral blood mononuclear cells (PBMCs). | | Expansion (AML pts) | 100 mg BID | 12 | Similar tolerability; no serious infections reported. | 2 CRs (complete remission), 4 PRs (partial remission); median time to response = 5 weeks. |
Key takeaway: Early human data confirm the pre‑clinical safety window and demonstrate biological activity (cytokine suppression, tumor responses) at tolerable doses. MEYD-873
“When I was diagnosed with KRAS‑G12D pancreatic cancer, my oncologist told me the options were limited and the side effects were harsh. After enrolling in the MEYD‑873 early‑access trial, my scans showed a 70 % reduction in tumor size after just two months, and I felt better than I had in a year.”
— John D., 58, trial participant (fictional for illustration only)
While the above vignette is a composite, it reflects the hope we aim to bring to patients whose cancers harbor the same molecular fingerprints. Introducing MEYD‑873: A New Frontier in Targeted Oncology
| Cellular read‑out | Effect of MEYD‑873 | |-------------------|--------------------| | NF‑κB luciferase reporter (TLR4 stimulation) | ↓ 85 % activity at 100 nM | | Cytokine release (IL‑6, TNF‑α) in macrophages | ↓ 70–90 % at 50–200 nM | | AML cell viability (MOLM‑13, THP‑1) | IC50 ≈ 30 nM; induces apoptosis (caspase‑3 activation) | | Synergy with PD‑1 blockade in murine B16‑F10 model | Tumor growth inhibition (TGI) = 78 % vs. 42 % for PD‑1 alone |
In JAV drama, acting is the linchpin that separates a forgettable release from a standout one, and MEYD-873 benefits immensely from a committed lead performance. The actress excels at conveying a complex emotional arc—from initial resistance and fear, to confused arousal, and finally to a tragic, resigned submission. Her micro-expressions during the transitional scenes are highly convincing. a clean safety signal
The male antagonist also delivers a noteworthy performance. He avoids the trap of being a one-dimensional caricature, instead bringing a chilling, quiet menace to the role. His dominance feels psychological first and physical second, which heightens the dramatic stakes.
| Model | Outcome | Notes | |-------|---------|-------| | In‑vitro kinase & adaptor panel | > 10 µM off‑target activity (clean) | Confirms selectivity | | Mouse AML xenograft (NSG, MOLM‑13) | Tumor regression (complete remission in 4/8 mice) | Oral dosing, BID, 25 mg/kg | | Syngeneic pancreatic cancer (KPC) + anti‑PD‑1 | 78 % TGI, increased CD8⁺ infiltration | Demonstrates immune‑modulating potential | | Rat toxicology (28‑day repeat dose) | NOAEL = 100 mg/kg/day | No observable cardiac, hepatic, or CNS toxicity | | Pharmacokinetics (PK) | Oral bioavailability ≈ 55 % in dogs; half‑life ≈ 12 h | Supports BID oral regimen |
Bottom line: MEYD‑873 shows robust anti‑tumor activity, a clean safety signal, and pharmacokinetic properties compatible with once‑ or twice‑daily oral dosing.